Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combo Clear all
Completed Phase 3 Interventional Results available

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

NCT03573817
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Revefenacin, Placebo, Formoterol
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
40 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 10, 2026, 2:45 PM EDT
Completed No phase listed Observational

Lung Disease Associated With Rheumatoid Arthritis

NCT00001876
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
21 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional

Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

NCT07130695
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Olutasidenib Investigational Agent Administration
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Investigation for the Preview® hCG Urine/Serum Combo Pregnancy Test

NCT04207554
View directory record Official record
Conditions
Pregnancy
Interventions
Test Device-Strip Format, Test Device-Cassette Format, Predicate Device
Device
Lead sponsor
Guangzhou Wondfo Biotech Co., Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
6
States / cities
Garden Grove, California • Huntington Park, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional

PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction

NCT05609097
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
PRIME, COMBO
Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

NCT04020185
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
IMSA101, Immune checkpoint inhibitor (ICI), Immuno-oncology (IO) therapy
Drug
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • La Jolla, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

NCT07382726
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Adagrasib, Iza-bren
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

NCT00613223
View directory record Official record
Conditions
Gliosarcoma, Glioblastoma
Interventions
Vandetanib and Etoposide
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors

NCT07095868
View directory record Official record
Conditions
Selected Types of Solid Tumor
Interventions
EVM14, Pembrolizumab
Biological · Combination Product
Lead sponsor
Everest Medicines (Beijing) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
New York, New York • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
MCLA-129, Osimertinib, Chemotherapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Not applicable Interventional

Combined NMES and BFR Training After TKA

NCT04347343
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Standard Rehabilitation + Neuromuscular Electrical Stimulation and Blood Flow Restriction
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 10, 2026, 2:45 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

NCT03445533
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tilsotolimod with Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

NCT00613132
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Gleevec, RAD001, and Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Phase I Study of TAS-106 in Combo With Carboplatin

NCT00752011
View directory record Official record
Conditions
Cancer, Solid Tumors
Interventions
TAS-106, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Sep 10, 2026, 2:45 PM EDT
Completed No phase listed Observational

Empowering Students Project

NCT05511298
View directory record Official record
Conditions
Relationship, Social
Interventions
Relationship Smarts Combo
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
Up to 23 Years
Enrollment
1,745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)

NCT01644175
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
76
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Black Bean Pasta Consumption on Biomarkers in Young Adults

NCT05182190
View directory record Official record
Conditions
Glucose, High Blood
Interventions
White bread, Black beans whole boiled, Knife Mill pasta, Combo Flour Pasta, Cyclone Flour Pasta
Dietary Supplement
Lead sponsor
Iowa State University
Other
Eligibility
21 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Ames, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Sep 10, 2026, 2:45 PM EDT
Active, not recruiting Phase 2 Interventional

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

NCT04413123
View directory record Official record
Conditions
Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Bradley A. McGregor, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Phase 1 Interventional

A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

NCT05753722
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC
Interventions
PRTH-101, Pembrolizumab
Biological
Lead sponsor
Incendia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Switch or Quit R01

NCT06373679
View directory record Official record
Conditions
Cigarette Smoking, Smoking Behaviors
Interventions
Switching to E-Cigarette, Switching using Medication
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Early Phase 1 Interventional

A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

NCT05555342
View directory record Official record
Conditions
Lung Tumor, Metastatic Cancer
Interventions
Irreversible electroporation (IRE) ablation, Radiation Therapy
Procedure · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 10, 2026, 2:45 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

NCT00011414
View directory record Official record
Conditions
Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
Interventions
Tariquidar
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 10, 2026, 2:45 PM EDT
Recruiting Phase 2 Interventional

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

NCT07415005
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Lorlatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 10, 2026, 2:45 PM EDT